Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - Deferred ChargesCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

BioXcel Therapeutics (BTAI) Other Gross PP&E Adjustments (2022 - 2025)

BioXcel Therapeutics has reported Other Gross PP&E Adjustments over the past 4 years, most recently at $814000.0 for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at $814000.0 for Q4 2025, up 9144.44% from a year ago — trailing twelve months through Dec 2025 was $814000.0 (up 9144.44% YoY), and the annual figure for FY2025 was $814000.0, up 9144.44%.
  • Other Gross PP&E Adjustments for Q4 2025 was $814000.0 at BioXcel Therapeutics, up from $712000.0 in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for BTAI hit a ceiling of $814000.0 in Q4 2025 and a floor of -$7.3 million in Q3 2023.
  • Median Other Gross PP&E Adjustments over the past 4 years was -$2.3 million (2022), compared with a mean of -$2.3 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: tumbled 803.09% in 2023 and later soared 9144.44% in 2025.
  • BioXcel Therapeutics' Other Gross PP&E Adjustments stood at -$1.7 million in 2022, then tumbled by 144.87% to -$4.3 million in 2023, then skyrocketed by 99.79% to -$9000.0 in 2024, then soared by 9144.44% to $814000.0 in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $814000.0 (Q4 2025), $712000.0 (Q3 2025), and $250000.0 (Q2 2025) per Business Quant data.